<DOC>
	<DOCNO>NCT02112526</DOCNO>
	<brief_summary>To characterize safety profile ACP-196 subject relapse refractory de Novo Activated B-cell ( ABC ) Subtype Diffuse Large B-Cell Lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>ACP-196 , Btk Inhibitor , Treatment de Novo Activated B-cell ( ABC ) Subtype Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Men woman ≥ 18 year age . Pathologically confirm de novo ABC DLBCL Relapsed refractory disease Subjects must ≥ 1 measurable disease sit A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism ACP196 , put study outcome undue risk Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification , LVEF &gt; 50 % Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Breast feeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>de Novo Activated B-cell ( ABC ) Subtype Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Novo Activated B-cell ( ABC )</keyword>
	<keyword>Novo Activated B-cell</keyword>
	<keyword>ABC DLBCL</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>B-Cell</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>